arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Kyverna Therapeutics, Inc.

KYTX Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$5.37
▼ -8.1% Today
as of Oct 23, 14:18 ET
Last 30 days -27.23% Sep 14 → Oct 23
$5.22 $5.83 $6.45 $7.06 $7.68 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$5.83
High
$5.98
Low
$5.67
Volume
$518,502
Avg Vol
$1M
Mkt Cap
$403M
P/E (TTM)
—
Beta
—
52w High
$13.67
52w Low
$5.61
Div Yield
—
Shares Out
$62M

Recent Press Releases & News last 60 days · 8 items

Oct 23 · 14:30 PR GlobeNewswire
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
Oct 21 · 11:15 PR GlobeNewswire
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
Oct 7 · 12:00 PR GlobeNewswire
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
▸ Show all 8 press releases & news Free account →

KYTX earnings at a glance

The options market is pricing a move of about ±27.5% after the report, a range of roughly $3.89 to $6.85 from today's $5.37. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±3.0% on average; after the most recent report on May 12, 2026 it moved -1.1%. That means options currently expect more movement than KYTX has typically delivered. KYTX beat the consensus EPS estimate in 4 of its last 4 reported quarters. Implied volatility is currently 233%. The share price of $5.37 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$5.61
$14
0% of range
Avg surprise (last 4)
+10.6%
Avg reaction (last 2)
+2.0%
50% positive
Latest IV / EM
233%
EM ±27.5% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-23.27$-17.20$-11.13$-5.07$1.00 Actual $-12.10Actual $-20.86Actual $-23.27Actual $-1.12Actual $-0.67Actual $-0.80Actual $-1.03Est $-1.21Actual $-0.97Est $1.00Actual $-0.85Est $-0.97Actual $-0.66Est $-0.75Actual $-0.63 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-45M$-43M$-40M$-38M$-36M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.63 — — — — financials
Tue May 12, 2026Mar/2026 $-0.66 $-0.75 +12.0% +35.9% -1.1% earnings
Wed Nov 12, 2025Sep/2025 $-0.85 $-0.97 +12.4% — — earnings
Tue Aug 12, 2025Jun/2025 $-0.97 $1.00 +3.0% — — earnings
Tue May 13, 2025Mar/2025 $-1.03 $-1.21 +14.9% — +5.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.80 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.67 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.12 — — — — financials
Sat Sep 30, 2023Sep 2023 $-23.27 — — — — financials
Fri Jun 30, 2023Jun 2023 $-20.86 — — — — financials
Fri Mar 31, 2023Mar 2023 $-12.10 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-40M$-41M—$-39M$-44M$-47M—$-39M
Net income$-38M$-40M—$-37M$-42M$-45M—$-34M
EPS (diluted)$-0.63$-0.66—$-0.85$-0.97$-1.03—$-0.80

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$32M$32M$124M$34M$53M$57M$97M$105M
Inventory————————
Total current assets$207M$242M$283M$175M$214M$248M$291M$325M
Total assets$220M$257M$294M$187M$227M$261M$305M$339M
Long-term debt$25M—$25M—————
Total liabilities$54M$61M$62M$35M$42M$37M$38M$36M
Total equity$166M$196M$232M$152M$184M$224M$267M$303M

Implied volatility — last 90 days

38%199%360%521%682% Jun 07 — IV 77% · EM ±10.7%Jun 08 — IV 91% · EM ±12.0%Jun 09 — IV 92% · EM ±11.5%Jun 10 — IV 88% · EM ±10.4%Jun 11 — IV 121% · EM ±13.3%Jun 12 — IV 115% · EM ±11.8%Jun 15 — IV 170% · EM ±12.3%Jun 16 — IV 192% · EM ±11.4%Jun 17 — IV 328% · EM ±13.7%Jun 19 — IV 300% · EM ±66.3%Jun 22 — IV 150% · EM ±31.3%Jun 23 — IV 130% · EM ±26.7%Jun 24 — IV 164% · EM ±32.8%Jun 25 — IV 168% · EM ±32.9%Jun 26 — IV 350% · EM ±66.9%Jun 29 — IV 322% · EM ±57.0%Jun 30 — IV 192% · EM ±33.1%Jul 01 — IV 215% · EM ±35.8%Jul 02 — IV 393% · EM ±63.6%Jul 03 — IV 407% · EM ±63.6%Jul 06 — IV 394% · EM ±54.6%Jul 07 — IV 47% · EM ±6.2%Jul 08 — IV 64% · EM ±8.1%Jul 09 — IV 52% · EM ±6.2%Jul 10 — IV 56% · EM ±6.1%Jul 13 — IV 39% · EM ±3.2%Jul 14 — IV 44% · EM ±3.1%Jul 15 — IV 54% · EM ±3.2%Jul 16 — IV 129% · EM ±5.4%Jul 20 — IV 101% · EM ±23.8%Jul 21 — IV 73% · EM ±17.0%Jul 22 — IV 77% · EM ±17.6%Jul 23 — IV 65% · EM ±14.5%Jul 24 — IV 131% · EM ±29.0%Jul 27 — IV 95% · EM ±19.9%Jul 28 — IV 85% · EM ±17.4%Jul 29 — IV 109% · EM ±21.9%Jul 30 — IV 65% · EM ±12.7%Jul 31 — IV 79% · EM ±15.1%Aug 03 — IV 118% · EM ±21.0%Aug 04 — IV 77% · EM ±13.2%Aug 05 — IV 71% · EM ±11.8%Aug 06 — IV 76% · EM ±12.3%Aug 07 — IV 221% · EM ±34.5%Aug 10 — IV 94% · EM ±13.0%Aug 11 — IV 153% · EM ±20.3%Aug 12 — IV 268% · EM ±33.5%Aug 13 — IV 42% · EM ±5.0%Aug 17 — IV 306% · EM ±25.6%Aug 18 — IV 374% · EM ±27.1%Aug 19 — IV 506% · EM ±29.9%Aug 24 — IV 142% · EM ±29.7%Aug 25 — IV 153% · EM ±31.4%Aug 26 — IV 128% · EM ±25.6%Aug 27 — IV 145% · EM ±28.4%Aug 28 — IV 206% · EM ±39.4%Sep 01 — IV 94% · EM ±16.2%Sep 02 — IV 179% · EM ±29.9%Sep 03 — IV 155% · EM ±25.1%Sep 04 — IV 175% · EM ±27.3%Sep 07 — IV 197% · EM ±27.3%Sep 08 — IV 117% · EM ±15.5%Sep 09 — IV 123% · EM ±15.4%Sep 11 — IV 106% · EM ±11.7%Sep 14 — IV 121% · EM ±10.1%Sep 15 — IV 288% · EM ±20.8%Sep 16 — IV 343% · EM ±20.2%Sep 17 — IV 577% · EM ±24.1%Sep 21 — IV 81% · EM ±16.9%Sep 22 — IV 75% · EM ±15.3%Sep 23 — IV 91% · EM ±18.3%Sep 24 — IV 100% · EM ±19.7%Sep 25 — IV 410% · EM ±78.6%Sep 28 — IV 131% · EM ±23.2%Sep 29 — IV 161% · EM ±27.8%Sep 30 — IV 229% · EM ±38.2%Oct 01 — IV 204% · EM ±33.0%Oct 02 — IV 525% · EM ±82.0%Oct 05 — IV 134% · EM ±18.6%Oct 06 — IV 682% · EM ±90.1%Oct 08 — IV 233% · EM ±27.5%

Sector peers

ZURA
Zura Bio Limited
$397M $3.39-17.9%
EDIT
Editas Medicine, Inc.
$387M $2.36-6.0%
AGEN
Agenus Inc.
$376M $6.32-1.3%
FENC
Fennec Pharmaceuticals Inc.
$365M $10.02-3.5%
TECX
Tectonic Therapeutic, Inc.
$444M $20.06-8.2%
CCCC
C4 Therapeutics, Inc.
$347M $3.05-3.8%

KYTX earnings FAQ

What is KYTX's expected move for earnings?

Options currently price a move of about ±27.5%, or $1.48 per share either way from $5.37.

How does KYTX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.0%, up 1 times and down 1 times.

What is KYTX's implied volatility?

KYTX's at-the-money implied volatility is about 233% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in